The Filings Report

GE HealthCare Technologies

GEHCNasdaqCIK 1932393Healthcare / Medical Devicesfiscal year ends December19 quarters since 2022

Revenue, Q3 FY2026
$5.5B
+7.2% on Q3 FY2025
Net income
$615M
+37.9% on Q3 FY2025
Free cash flow
$793M
+64.2% on Q3 FY2025
Diluted EPS
$1.36
+38.8% on Q3 FY2025
Revenue, TTM
$21.6B
trailing four quarters
Net margin, TTM
10.0%
net income $2.2B
Free cash flow, TTM
—
Cash and equivalents
$2.8B
long-term debt $10.0B, Sep 30, 2026
Shares, 12-month change
−0.7%
452M shares, Sep 30, 2026
Buybacks, TTM
$300M
0.9% of market value
Dividends, TTM
$64M
0.2% of market value
Market value
$34.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 28, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, GE HealthCare Technologies reported revenue of $5.5B, +7.2% on Q3 FY2025, and net income of $615M (+37.9%). Operating margin was 14.6%. Free cash flow, operating cash flow less capital expenditures, was $793M ($907M less $114M). Diluted earnings per share were $1.36.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 28, 2026.

Revenue and net incomeRevenueNet income
$0$2B$4B$6BQ4'22, Revenue: $4.9BQ4'22, Net income: $554MQ4'22Q1'23, Revenue: $4.7BQ1'23, Net income: $372MQ1'23Q2'23, Revenue: $4.8BQ2'23, Net income: $418MQ2'23Q3'23, Revenue: $4.8BQ3'23, Net income: $375MQ3'23Q4'23, Revenue: $5.2BQ4'23, Net income: $403MQ4'23Q1'24, Revenue: $4.7BQ1'24, Net income: $374MQ1'24Q2'24, Revenue: $4.8BQ2'24, Net income: $428MQ2'24Q3'24, Revenue: $4.9BQ3'24, Net income: $470MQ3'24Q4'24, Revenue: $5.3BQ4'24, Net income: $721MQ4'24Q1'25, Revenue: $4.8BQ1'25, Net income: $564MQ1'25Q2'25, Revenue: $5.0BQ2'25, Net income: $486MQ2'25Q3'25, Revenue: $5.1BQ3'25, Net income: $446MQ3'25Q4'25, Revenue: $5.7BQ4'25, Net income: $589MQ4'25Q1'26, Revenue: $5.1BQ1'26, Net income: $389MQ1'26Q2'26, Revenue: $5.3BQ2'26, Net income: $561MQ2'26Q3'26, Revenue: $5.5BQ3'26, Net income: $615MQ3'26$0$2B$4B$6BQ4'22, Revenue: $4.9BQ4'22, Net income: $554MQ1'23, Revenue: $4.7BQ1'23, Net income: $372MQ1'23Q2'23, Revenue: $4.8BQ2'23, Net income: $418MQ3'23, Revenue: $4.8BQ3'23, Net income: $375MQ3'23Q4'23, Revenue: $5.2BQ4'23, Net income: $403MQ1'24, Revenue: $4.7BQ1'24, Net income: $374MQ1'24Q2'24, Revenue: $4.8BQ2'24, Net income: $428MQ3'24, Revenue: $4.9BQ3'24, Net income: $470MQ3'24Q4'24, Revenue: $5.3BQ4'24, Net income: $721MQ1'25, Revenue: $4.8BQ1'25, Net income: $564MQ1'25Q2'25, Revenue: $5.0BQ2'25, Net income: $486MQ3'25, Revenue: $5.1BQ3'25, Net income: $446MQ3'25Q4'25, Revenue: $5.7BQ4'25, Net income: $589MQ1'26, Revenue: $5.1BQ1'26, Net income: $389MQ1'26Q2'26, Revenue: $5.3BQ2'26, Net income: $561MQ3'26, Revenue: $5.5BQ3'26, Net income: $615MQ3'26

Net income losses drawn in red.

Free cash flow
−$250M$0$250M$500M$750M$1.0BQ4'22Q1'23, Free cash flow: $325MQ1'23Q2'23, Free cash flow: −$137MQ2'23Q3'23, Free cash flow: $570MQ3'23Q4'23Q1'24, Free cash flow: $274MQ1'24Q2'24, Free cash flow: −$183MQ2'24Q3'24Q4'24Q1'25, Free cash flow: $98MQ1'25Q2'25, Free cash flow: $8MQ2'25Q3'25, Free cash flow: $483MQ3'25Q4'25Q1'26, Free cash flow: $112MQ1'26Q2'26, Free cash flow: $68MQ2'26Q3'26, Free cash flow: $793MQ3'26−$250M$0$250M$500M$750M$1.0BQ1'23, Free cash flow: $325MQ1'23Q2'23, Free cash flow: −$137MQ3'23, Free cash flow: $570MQ3'23Q1'24, Free cash flow: $274MQ1'24Q2'24, Free cash flow: −$183MQ3'24Q1'25, Free cash flow: $98MQ1'25Q2'25, Free cash flow: $8MQ3'25, Free cash flow: $483MQ3'25Q1'26, Free cash flow: $112MQ1'26Q2'26, Free cash flow: $68MQ3'26, Free cash flow: $793MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15BQ4'22, Cash and equivalents: $1.4BQ4'22, Long-term debt: $8.2BQ4'22Q1'23, Cash and equivalents: $2.3BQ1'23, Long-term debt: $10.2BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $10.2BQ2'23Q3'23, Cash and equivalents: $2.4BQ3'23, Long-term debt: $10.3BQ3'23Q4'23, Cash and equivalents: $2.5BQ4'23, Long-term debt: $8.4BQ4'23Q1'24, Cash and equivalents: $2.6BQ1'24, Long-term debt: $8.2BQ1'24Q2'24, Cash and equivalents: $2.0BQ2'24, Long-term debt: $8.2BQ2'24Q3'24, Cash and equivalents: $3.5BQ3'24, Long-term debt: $9.3BQ3'24Q4'24, Cash and equivalents: $2.9BQ4'24, Long-term debt: $7.4BQ4'24Q1'25, Cash and equivalents: $2.5BQ1'25, Long-term debt: $6.8BQ1'25Q2'25, Cash and equivalents: $3.7BQ2'25, Long-term debt: $8.3BQ2'25Q3'25, Cash and equivalents: $4.0BQ3'25, Long-term debt: $8.3BQ3'25Q4'25, Cash and equivalents: $4.5BQ4'25, Long-term debt: $9.5BQ4'25Q1'26, Cash and equivalents: $2.3BQ1'26, Long-term debt: $10.1BQ1'26Q2'26, Cash and equivalents: $2.1BQ2'26, Long-term debt: $10.1BQ2'26Q3'26, Cash and equivalents: $2.8BQ3'26, Long-term debt: $10.0BQ3'26$0$5B$10B$15BQ4'22, Cash and equivalents: $1.4BQ4'22, Long-term debt: $8.2BQ1'23, Cash and equivalents: $2.3BQ1'23, Long-term debt: $10.2BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $10.2BQ3'23, Cash and equivalents: $2.4BQ3'23, Long-term debt: $10.3BQ3'23Q4'23, Cash and equivalents: $2.5BQ4'23, Long-term debt: $8.4BQ1'24, Cash and equivalents: $2.6BQ1'24, Long-term debt: $8.2BQ1'24Q2'24, Cash and equivalents: $2.0BQ2'24, Long-term debt: $8.2BQ3'24, Cash and equivalents: $3.5BQ3'24, Long-term debt: $9.3BQ3'24Q4'24, Cash and equivalents: $2.9BQ4'24, Long-term debt: $7.4BQ1'25, Cash and equivalents: $2.5BQ1'25, Long-term debt: $6.8BQ1'25Q2'25, Cash and equivalents: $3.7BQ2'25, Long-term debt: $8.3BQ3'25, Cash and equivalents: $4.0BQ3'25, Long-term debt: $8.3BQ3'25Q4'25, Cash and equivalents: $4.5BQ4'25, Long-term debt: $9.5BQ1'26, Cash and equivalents: $2.3BQ1'26, Long-term debt: $10.1BQ1'26Q2'26, Cash and equivalents: $2.1BQ2'26, Long-term debt: $10.1BQ3'26, Cash and equivalents: $2.8BQ3'26, Long-term debt: $10.0BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

GE HealthCare Technologies income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue5,5135,2955,1315,6985,1435,0074,7775,319+7.2%
Cost of revenue—————————
Gross profit2,2242,1801,9772,2611,9901,9852,0122,275+11.8%
Research and development320323345323292302344344+9.6%
Selling, general and administrative1,1001,1181,1171,1111,0451,0291,0401,130+5.3%
Operating income805739515827653654629801+23.3%
Other income (expense)1922363326(1)9954−26.9%
Pretax income752693505821643613692834+17.0%
Income tax1291199421917911310496−27.9%
Net income615561389589446486564721+37.9%
Diluted EPS ($)1.361.240.85—0.981.061.23—+38.8%
Diluted shares (millions)453454457—457458459——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

GE HealthCare Technologies balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents2,8262,0792,2614,4924,0053,7372,4542,874−29.4%
Short-term investments—————————
Total current assets11,49510,49710,42612,50111,89311,3089,7359,901−3.3%
Total assets38,37137,24637,12536,90636,12735,50033,58633,089+6.2%
Total current liabilities8,8158,3028,5299,10510,0739,7489,9699,553−12.5%
Long-term debt9,97010,09110,1279,4958,2778,2706,7577,449+20.5%
Total liabilities26,50826,02726,22726,30725,90725,54824,16824,437+2.3%
Stockholders’ equity11,61410,97510,66810,3799,9939,7129,1878,446+16.2%
Shares outstanding (millions)452452455456456457458457—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

GE HealthCare Technologies cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow907168290—59394250—+53.0%
Capital expenditures11410017813411086152102+3.6%
Free cash flow (CFO − capex)79368112—483898—+64.2%
Depreciation and amortization—————————
Share repurchases0200100010010000−100.0%
Dividends paid16161616161616140.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 4, 2026.

Income statement

GE HealthCare Technologies income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 6, 2024FY2022ended Dec 31, 2022filed Apr 25, 2023FY2021ended Dec 31, 2021filed Feb 6, 2024
Revenue20,62519,67219,55218,34117,585
Cost of revenue—————
Gross profit8,2488,2057,9227,1797,174
Research and development1,2601,3111,2051,026816
Selling, general and administrative4,2254,2694,2823,6313,563
Operating income2,7632,6252,4352,5222,795
Other income (expense)157558662123
Pretax income2,7682,5812,3612,5122,875
Income tax614531743563600
Net income2,0841,9931,5681,9162,247
Diluted EPS ($)4.554.343.034.224.95
Diluted shares (millions)458459458454454

Balance sheet

GE HealthCare Technologies balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 6, 2024FY2022ended Dec 31, 2022filed Apr 25, 2023FY2021ended Dec 31, 2021filed Feb 6, 2024
Cash and equivalents4,4922,8742,4941,440—
Short-term investments—————
Total current assets12,5019,9019,4108,318—
Total assets36,90633,08932,45427,539—
Total current liabilities9,1059,5538,9817,191—
Long-term debt9,4957,4498,4368,234—
Total liabilities26,30724,43725,14417,947—
Stockholders’ equity10,3798,4467,1339,357—
Shares outstanding (millions)456457455454—

Cash flow statement

GE HealthCare Technologies cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 6, 2024FY2022ended Dec 31, 2022filed Apr 25, 2023FY2021ended Dec 31, 2021filed Feb 6, 2024
Operating cash flow—————
Capital expenditures482401387310248
Free cash flow (CFO − capex)—————
Depreciation and amortization—————
Share repurchases20000——
Dividends paid64554100

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$6M
8 purchases by 8 insiders; officers and directors $6M
Sold, twelve months
$0
0 sales by 0 insiders; officers and directors $0

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 14, 2026Grogan William KChief Financial Officeraward62,256$0.00—62,256Sep 16, 2026
Sep 14, 2026Grogan William KChief Financial Officeraward12,840$0.00—75,096Sep 16, 2026
Sep 3, 2026Rackliffe PhilipCEO, AIStax withholding798$70.56$56K41,533Sep 4, 2026
Sep 3, 2026O'Neill Kevin MichaelCEO, PDxtax withholding718$70.56$51K32,026Sep 4, 2026
Sep 3, 2026Newcomb George A.Chief Accounting Officertax withholding112$70.56$8K10,515Sep 4, 2026
Sep 3, 2026Kass-Hout TahaChief Technology Officertax withholding1,502$70.56$106K88,467Sep 4, 2026
Sep 3, 2026Jimenez Frank RGC & Corporate Secretarytax withholding1,480$70.56$104K89,321Sep 4, 2026
Sep 3, 2026Holton Adam YChief People Officertax withholding673$70.56$47K19,533Sep 4, 2026
Sep 3, 2026Estrampes CatherineChief Commer. & Growth Officertax withholding508$70.56$36K23,573Sep 4, 2026
Sep 3, 2026Arduini Peter JPresident and CEO, Directortax withholding6,303$70.56$445K241,606Sep 4, 2026
Sep 1, 2026Rackliffe PhilipCEO, AIStax withholding290$71.23$21K42,897Sep 3, 2026
Sep 1, 2026Rackliffe PhilipCEO, AIStax withholding226$71.23$16K42,671Sep 3, 2026
Sep 1, 2026Rackliffe PhilipCEO, AIStax withholding340$71.23$24K42,331Sep 3, 2026
Sep 1, 2026Kass-Hout TahaChief Technology Officertax withholding1,644$71.23$117K91,265Sep 3, 2026
Sep 1, 2026Kass-Hout TahaChief Technology Officertax withholding1,296$71.23$92K89,969Sep 3, 2026
Sep 1, 2026Jimenez Frank RGC & Corporate Secretarytax withholding1,751$71.23$125K92,181Sep 3, 2026
Sep 1, 2026Jimenez Frank RGC & Corporate Secretarytax withholding1,380$71.23$98K90,801Sep 3, 2026
Sep 1, 2026Holton Adam YChief People Officertax withholding659$71.23$47K20,206Sep 3, 2026
Sep 1, 2026Bankes JeannetteCEO, Patient Care Solutionstax withholding1,064$71.23$76K37,293Sep 3, 2026
Sep 1, 2026Arduini Peter JPresident and CEO, Directortax withholding6,043$71.23$430K253,381Sep 3, 2026
Sep 1, 2026Arduini Peter JPresident and CEO, Directortax withholding5,472$71.23$390K247,909Sep 3, 2026
Aug 15, 2026Holton Adam YChief People Officertax withholding1,360$73.69$100K20,865Aug 18, 2026
May 22, 2026Lobo KevinDirectoropen-market buy10,000$64.18$642K14,363May 26, 2026
May 15, 2026Rackliffe PhilipCEO, AISaward16,458$0.00—43,187May 19, 2026
May 15, 2026Bankes JeannetteCEO, Patient Care Solutionstax withholding5,535$62.67$347K38,357May 19, 2026

Full insider history for GE HealthCare Technologies, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held GEHC in their latest 13F filing, through August 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded GEHC by quarter.

FundManagerQuarterValueSharesWeightMove
Trian Fund ManagementNelson PeltzQ2 2026$197M3M4.67%added +76194.4%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
GE HEALTHCARE TECHNOLOGIES INC., CIK 1932393 on EDGAR
Extract generated
October 29, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: not filed
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 29, 2026.

JSON file
/data/financials/GEHC.json